Breaking News

MJFF Awards $1.4M Grant to Bexion Pharmaceuticals for Parkinson’s Research

The grant will fund the preclinical development of BXQ-350.

Author Image

By: Charlie Sternberg

Associate Editor

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) awarded a $1.4M grant to Bexion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN). The grant will fund the preclinical development of BXQ-350 for the treatment of Parkinson’s disease (PD).   “We are grateful and honored to receive this generous grant from The Michael J. Fox ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters